We showed in glioblastoma cells that therapeutically relevant doses (<50 μM) of TMZ are effective in activating the ATR/ATM-SIAH1/HIPK2-p53Ser46 axis and thus trigger apoptosis [45]. The gene discussed is HIPK2; the disease is glioblastoma.